Valuation: Thiogenesis Therapeutics, Corp.

Market Cap 34.99M 25.01M 21.78M 20.61M 18.73M 2.39B 35.16M 246M 94.94M 1.22B 93.94M 91.85M 3.9B P/E 2024
-8.65x
P/E 2025 -4.25x
Enterprise Value 33.37M 23.85M 20.78M 19.66M 17.86M 2.28B 33.54M 234M 90.56M 1.16B 89.6M 87.61M 3.72B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.91%
Yield 2024 *
-
Yield 2025 -
1 week-7.41%
Current month-7.41%
1 month-9.09%
3 months-12.28%
6 months+2.04%
Current year-23.08%
1 week 0.48
Extreme 0.48
0.52
1 month 0.48
Extreme 0.48
0.58
Current year 0.44
Extreme 0.44
0.66
1 year 0.44
Extreme 0.44
0.81
3 years 0.44
Extreme 0.44
1.06
5 years 0.38
Extreme 0.375
1.06
10 years 0.38
Extreme 0.375
1.06
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2022
Chief Executive Officer 60 -
Director TitleAgeSince
Chairman 73 31/03/2022
Director/Board Member 75 31/03/2022
Director/Board Member 60 03/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
6/1/26 A Sell

Director

150,000 0.2894%
9/11/25 A Option

Director

75,000 0.1702%
8/1/25 A Sell

Director

64,000 0.1453%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.41%-30.56%-30.56% 25.11M
+1.23%+1.30%-0.69%+9.57% 45.91B
+0.23%+4.85%+44.23%+27.27% 44.25B
+0.52%-5.17%+340.58%+520.09% 41.99B
+1.55%+0.70%+8.03%+76.45% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
-0.20%+4.93%+25.35%+119.72% 17.21B
-3.49%-8.35% - - 16.27B
+2.92%+8.37%+22.73%+38.87% 14.96B
-2.45%+6.38%-1.99%-35.16% 13.42B
Average +0.32%+1.19%+46.66%+85.26% 26.47B
Weighted average by Cap. +0.77%+0.68%+71.14%+120.59%

Financials

2024 2025
Net sales - -
Net income -3.15M -2.25M -1.96M -1.85M -1.68M -215M -3.16M -22.07M -8.54M -109M -8.45M -8.26M -350M -7.43M -5.31M -4.62M -4.38M -3.98M -508M -7.46M -52.11M -20.15M -258M -19.94M -19.49M -827M
Net Debt -3.85M -2.75M -2.4M -2.27M -2.06M -263M -3.87M -27M -10.44M -134M -10.33M -10.1M -428M -1.62M -1.15M -1.01M -952K -865K -111M -1.62M -11.34M -4.38M -56.21M -4.34M -4.24M -180M
Logo Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.
Employees
-
Date Price Change Volume
17/09/26 CA$0.5000 0.00% 16,500
16/09/26 CA$0.5000 0.00% 2,500
15/09/26 CA$0.5000 0.00% 90,000
14/09/26 CA$0.5000 -1.96% 43,000
11/09/26 CA$0.5100 0.00% 28,000

Net sales - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!